Antisense therapy

Current Opinion in Oncology

Volumn 8, Issue 6, 1996, Pages 509-515

  Narayanan, Ramaswamy ^a   Akhtar, Saghir ^b  

^a HOFFMANN LA ROCHE INC   (United States)

^b ASTON UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; BCR ABL PROTEIN; COMPLEMENTARY RNA; DNA POLYMERASE; LIPOSOME; OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATE; ONCOPROTEIN; PROTEIN BCL 2; PROTEIN KINASE C; PROTEIN TYROSINE KINASE; RIBONUCLEASE; RNA DIRECTED DNA POLYMERASE; TRANSCRIPTION FACTOR; UROKINASE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ACUTE GRANULOCYTIC LEUKEMIA; CANCER THERAPY; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DRUG DELIVERY SYSTEM; DRUG MECHANISM; FOLLICULAR LYMPHOMA; GENE EXPRESSION; GENE TARGETING; GENE THERAPY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; NUCLEIC ACID PROBE; ONCOGENE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REVIEW; SUSTAINED RELEASE PREPARATION;

EID: 0029853413     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-199611000-00011     Document Type: Review

References (66)

1. Stein CA, Cheng YC: Antisense oligonucleotides as therapeutic agents: Is the bullet really magical? Science 1993, 261:1004-1012.
2. Stein CA, Narayanan R: Antisense oligonucleotides. Curr Opin Oncol 1994, 6:587-594.
3. Sharma HW, Narayanan R: The therapeutic potential of antisense oligodeoxynucleotides. Bioessays 1995, 17:1055-1063. A review of the current status of antisense, from the laboratory to the clinic. Nonspecificity of antisense is discussed in detail.
4. Helene C, Toulme JJ: Specific regulation of gene expression by antisense, sense and antigene nucleic acids. Biochim Biophys Acta 1990, 1049:99-125.
5. Nesterova M, Cho-Chung YW: A single-injection protein kinase A- directed antisense treatment to inhibit tumour growth. Nature Med 1995, 1:528-533. A single injection of the antisense ODNs caused pronounced tumor inhibition in vivo. The growth inhibition persisted, even after RIα inhibition was lost, so long as PKA-1 (the RIα-containing holoenzyme) downregulation was present. Results suggest that certain antisense ODNs may require relatively infrequent repetitive dosing for in vivo efficacy.
6. Tan TMC, Ting RCY: In vitro and in vivo inhibition of human papillomavirus type 16 E6 and E7 genes. Cancer Res 1995, 55:4599-4605.
7. 50 0.06-0.6 mg/kg) of the antisense PS ODN was seen in these studies. Following a single intravenous administration (at 6 mg/kg), accumulation of antisense ODN at 10 to 50 μm was seen in tumors. The study seems to suggest that tumors may be more sensitive to c-raf inhibition than normal cells, and that c-raf antisense may be effective in multiple tumors. Detailed studies with tumors containing different ras mutations are needed, however, to clarify the impact of this molecular target.
8. Huang Y, Snyder R, Kligshteyn M, Wickstrom E: Prevention of tumor formation in a mouse model of Burkitt's lymphoma by 6 weeks of treatment with anti-c-myc DNA phosphorothioate. Mol Med 1995, 1:647-658.
9. Wickstrom E, Bacon T, Wickstrom EL: Down-regulation of c-MYC antigen expression in lymphocytes of Emu-c-myc transgenic mice treated with anti-c-myc DNA methylphosphonates. Cancer Res 1992, 52:6741-6745.
10. Moriya K, Matsukura M, Kurokawa K, Koike K: In vivo inhibition of hepatitis B virus gene expression by antisense phosphorothioate oligonucleotides. Biochem Biophys Res Commun 1996, 218:217-223.
11. Skorski T, Nieborowska-Skorska M, Campbell K, Iozzo RV, Zon G, Darzynkiewicz Z, Calabretta B: Leukemia treatment in severe combined immunodeficieny mice by antisense oligodeoxynucleotides targeting cooperating oncogenes. J Exp Med 1995, 182:1645-1653. Cancer is seen together with multiple genetic defects. Single-gene targeting may not be efficacious owing to alternative pathways. This report demonstrates the potential of targeting multiple genes in cancer therapy. The use of multiple antisense ODNs can, however, increase the complexity of interpretations.
12. Yaswen P, Stampfer MR, Ghosh K, Cohen JS: Effects of sequence of thioated oligonucleotides on cultured human mammary epithelial cells. Antisense Res Dev 1993, 3:67-77.
13. Maltese JY, Vassilev L, Sharma HW, Narayanan R: Sequence context of antisense RelA/NF-κB phosphorothioates determines specificity. Nucleic Acids Res 1995, 7:1146-1151. A set of contiguous dG residues in an ODN (ie, a G quartet, 4 Gs) is believed to contribute to undefined nonspecificity. A systematic analysis of refA antisense PS ODN, which contains a G quartet, was made by designing more than 40 ODNs with the G quartet in varying positions. Results indicate that generalization with reference to the presence of a G quartet in an ODN cannot be made. The context, ie, the sequences that surround the G quartet, is the critical factor for the G quartet to exert its effect.
14. Bergan R, Connell Y, Fahmy B, Kyle E, Neckers L: Aptameric inhibition of p210 bcr-abl tyrosine kinase autophosphorylation by oligodeoxynucleotides of defined sequence and backbone structure. Nucleic Acids Res 1994, 22:2150-2154.
15. Wilhelm O, Schmitt M, Hohl S, Senekowitsch R, Graeff H: Antisense inhibition of urokinase reduces spread of human ovarian cancer in mice. Clin Exp Metastasis 1995, 13:296-302.
16. Morishita R, Gibbons GH, Horiuchi M, Ellison KE, Nakajima M, Zhang L, Kaneda Y, Ogihara T, Dzau VJ: A gene therapy strategy using a transcription factor decoy of the E2F binding site inhibits smooth muscle proliferation in vivo. Proc Natl Acad Sci U S A 1995, 92:5855-5859. Transcription factors bind to a distinct set of DNA sequences with high affinity. This report demonstrates that transcription factor function in vivo can be blocked by a double-stranded PS ODN (transcription factor decoy [TFD]), which acts as a competitor. This is the first report of the use of a TFD in a preclinical model. While nonspecific components of PS ODNs may still play a part, the TFD approach provides a nonantisense mechanism for downregulation of transcription factor function. For details of the TFD approach, see Sharma et al. (Anticancer Res 1996, 16:61-70).
17. Sharma HW, Higgins-Sochaski KA, Perez JR, Narayanan R: A DNA motif present in αV integrin promoter exhibits dual binding preference to distinct transcription factors. Anticancer Res 1995, 15:1857-1868.
18. Goldring CE, Narayanan R, Lagadec P, Jeannin JF: Transcriptional inhibition of the inducible nitric oxide synthese gene by competitive binding of NF-κ/Rel proteins. Biochem Biophys Res Commun 1995, 209:73-79.
19. Lin KI, Lee SH, Narayanan R, Baraban JM, Hardwick JM, Ratan RR: Thiol agents and Bcl-2 identify an alphavirus-induced apoptotic pathway that requires activation of the transcription factor NF-kappa B. J Cell Biol 1995, 131:1149-1161.
20. Sharma HW, Perez JR, Higgins-Sochaski KA, Hsiao R, Narayanan R: Transcription factor decoy approach to decipher the role of NF-κB in oncogenesis. Anticancer Res 1996, 16:61-70. This report details the basis of the TFD approach to inhibiting transcription factor function. For a ubiquitous transcription factor such as NF-κB, homo- or heterodimers can be selectively targeted by the TFD approach.
21. Vaughn JP, Iglehart JD, Demirdji S, Davis P, Babiss LE, Caruthers MH, Marks JR: Antisense DNA downregulation of the ERBB2 oncogene measured by a flow cytometric assay. Proc Natl Acad Sci U S A 1995, 92:8336-8342. This report describes a novel approach to examining antisense effects that allows simultaneous measurement of antisense dose and gene-specific regulation on a per-cell basis. An antisense PS ODN to erB2 was codelivered with a fluorescein isothiocyanate-labeled ODN, and two-color flow cytometry was used to trace the fate of the ODNs. Results support previous contentions that only within a narrow dose range does an antisense PS ODN exhibit activity.
22. Santra M, Skorski T, Calabretta B, Lattime EC, Iozzo RV: De novo decorin gene expression suppresses the malignant phenotype in human colon cancer cells. Proc Natl Acad Sci U S A 1995, 92:7016-7020.
23. Sakakura C, Hagiwara A, Tsujimoto H, Ozaki K, Sakakibara T, Oyama T, Ogaki M, Imanishi T, Yamazaki J, Takahashi T: Inhibition of colon cancer cell proliferation by antisense oligonucleotides targeting the messenger RNA of the Ki-ras gene. Anticancer Drugs 1995, 6:553-561.
24. Stewart AJ, CanitRot Y, Baracchini E, Dean NM, Deeley RG, Cole SPC: Reduction of expression of the multidrug resistance protein (MRP) in human tumor cells by antisense phosphorothioate oligonucleotides. Biochem Pharmacol 1996, 51:461-469.
25. Mahon FX, Ripoche J, Pigeonnier V, Jazwiec B, Pigneux A, Moreau JF, Reiffers J: Inhibition of chronic myelogenous leukemia cells harboring a BCR-ABL B3A2 junction by antisense oligonucleotides targeted at the B2A2 junction. Exp Hematol 1995, 23:1606-1611.
26. Keller ET, Ershler WB: Effect of IL-6 receptor antisense oligodeoxynucleotide on in vitro proliferation of myeloma cells. J Immunol 1995, 154:4091-4098.
27. Walker TL, White JD, Esdale WJ, Burton MA, Decruz EE: Tumour cells surviving in vivo cisplatin chemotherapy display elevated c-myc expression. Br J Cancer 1996, 73:610-614.
28. Normanno N, Selvam MP, Bianco C, Damiano V, De Angelis E, Grassi M, Magliulo G, Tortora G, Salomon DS, Ciardiello F: Amphiregulin antisense oligodeoxynucleotides inhibit growth and transformation of a human colon carcinoma cell line. Int J Cancer 1995, 62:762-766.
29. Smith MR, Abubakr Y, Mohammad R, Xie T, Hamdan M, Al-Katib A: Antisense oligodeoxyribonucleotide down-regulation of bcl-2 gene expression inhibits growth of the low-grade non-Hodgkin's lymphoma cell line WSU-FSCCL. Cancer Gene Ther 1995, 2:207-212.
30. Gibson LF, Piktel D, Narayanan R, Nunez G, Landreth KS: Stromal cells regulate bcl-2 and bax expression in pro-B cells. Exp Hematol 1996, 24:628-637.
31. Dosaka-Akita H, Akie K, Hiroumi H, Kinoshila I, Kawakami Y, Murakami A: Inhibition of proliferation by L-myc antisense DNA for the translational initiation site in human small cell lung cancer. Cancer Res 1995, 55:1559-1564.
32. Akino K, Ohtsuru A, Yano H, Ozeki S, Namba H, Nakashima M, Ito M, Matsumoto T, Yamashita S: Antisense inhibition of parathyroid hormone related peptide gene expression reduces malignant pituitary tumor progression and metastases in the rat Cancer Res 1996, 56:77-86.
33. Macleod AR, Szyf M: Expression of antisense to DNA methyltransferase mRNA induces DNA demethylation and inhibits tumorigenesis. J Biol Chem 1995, 270:8037-8043.
34. Fakhrai H, Dorigo O, Shawler DL, Lin H, Mercola D, Black KL, Royston I, Sobol RE: Eradication of established intracranial rat gliomas by transforming growth factor β antisense gene therapy. Proc Natl Acad Sci U S A 1996, 93:2909-2914.
35. Huang F, Newman E, Theodorescu D, Kerbel RS, Friedman E: Transforming growth factor β1 (TGFβ1) is an autocrine positive regulator of colon carcinoma U9 cells in vivo as shown by transfection of a TGFβ1 antisense expression plasmid. Cell Growth Differ 1995, 6:1635-1642.
36. Saleh M, Stacker SA, Wilks AF: Inhibition of growth of C6 glioma cells in vivo by expression of antisense vascular endothelial growth factor sequence. Cancer Res 1996, 56:393-401.
37. Arteaga CL, Holt JT: Tissue-targeted antisense c-fos retroviral vector inhibits established breast cancer xenografts in nude mice. Cancer Res 1996, 56:1098-1103. Inhibition of c-fos oncogene mediated by a retroviral vector was achieved in a tissue-specific manner (breast). Growth and invasion of MCF-7 breast carcinoma was inhibited by in vivo injection of the retroviral antisense. This study provides a rationale for targeted gene therapy in breast cancer.
38. Cheng JQ, Ruggeri B, Klein WM, Sonada G, Altomare DA, Watson DK, Testa JR: Amplification of AKT2 in human pancreatic cancer cells and inhibition of AKT2 expression and tumorigenicitiy by antisense RNA. Proc Natl Acad Sci U S A 1996, 93:3636-3641.
39. Zhou P, Jiang W, Zhang Y, Kahn SM, Schieren I, Santella RM, Weinstein IB: Antisense to cyclin D1 inhibits growth and reverses the transformed phenotype of human esophageal cancer cells. Oncogene 1995, 11:571-580.
40. Neuenschwander S, Roberts CT JR, Leroith D: Growth inhibition of MCF-7 breast cancer cells by stable expression of an insulin-like growth factor I receptor antisense ribonucleic acid. Endocrinology 1995, 136:4298-4303.
41. Maret A, Galy B, Arnaud E, Bayard F, Prats H: Inhibition of fibroblast growth factor 2 expression by antisense RNA induced a loss of the transformed phenotype in a human hepatoma cell line. Cancer Res 1995, 55:5075-5079.
42. Velasco JA, Stevens CW, Esteban JM, Ruthsatz MK, Ramsamooj P, Dritschilo A, Notario V: Modulation of proliferation and tumorigenic potential of cervical cercinoma cells by the expression of sense and antisense p53. Int J Oncol 1995, 7:883-888.
43. Chakrabarty S, Rajagopal S, Huang S: Expression of antisense epidermal growth factor receptor RNA downmodulates the malignant behavior of human colon cancer cells. Clin Exp Metastasis 1995, 13:191-195.
44. Aoki K, Yoshida T, Sugimura T, Terada M: Liposome-mediated in vivo gene transfer of antisense K-ras construct inhibits pancreatic tumor dissemination in the murine peritoneal cavity. Cancer Res 1995, 55:3810-3816. This study documents the use of liposomes to deliver an antisense construct into the peritoneum of nude mice bearing tumors. Injected DNA was detected in multiple tissues (except brain) at day 24. No treatment-related toxicity was seen. This method may offer an effective alternative to viral vectors for gene therapy.
45. Feng M, Cabrera G, Deshane J, Scanlon KJ, Curiel DT: Neoplastic reversion accomplished by high efficiency adenoviral-mediated delivery of an anti-ras ribozyme. Cancer Res 1995, 55:2024-2028. This is the first demonstration of an adenovirus-based vector for delivery of a ribozyme construct in mice.
46. Feng J, Funk WD, Wang SS, Weinrich SL, Avilion AA, Chiu CP, Adams RR, Chang E, Allsopp RC, Yu J, Le S, West MD, Harley CB, Andrews WH, Greider GW, Villeponteau B: The RNA component of human telomerase. Science 1995, 269:1236-1241.
47. Akhtar S, ed: Delivery Strategies for Antisense Oligonucleotide Therapeutics. Boca Raton, FI: CRC Press, Inc.; 1995. This comprehensive volume reviews the major hurdles to oligonucleotide delivery and discusses many of the current strategies being developed for the improved delivery and targeting of oligonucleotides to desired sites of the body.
48. Chin D, Green G, Zon G, Szoka F, Straubinger R: Rapid nuclear accumulation of injected oligodeoxyribonucleotides. New Biol 1990, 12:1091-1100.
49. Walker I, Irwin WJ, Akhtar S: Improved cellular delivery of antisense oligonucleotides using transferrin receptor antibody-oligonucleotide conjugates. Pharm Res 1995, 12:1548-1553. Transferrin receptor antibodies have been used in the past to deliver peptides and small-molecular-weight compounds. This report documents the delivery of ODNs by coupling to the antibody. It is conceivable that such coupling may enable the delivery of ODNs across the blood-brain barrier, since the microvessel endothelial cells in the barrier have an abundance of the transferrin receptor.
50. Lewis KJ, Irwin WJ, Akhtar S: Biodegradable poly(L-lactic acid) matrices for the sustained delivery of antisense oligonucleotides. J Controlled Rel 1996, 37:173-183. Uptake of ODNs by cells is poor; nontoxic delivery systems are crucial to efficacy. This preliminary report demonstrates the potential utility of a biodegradable poly(L-lactic acid) matrix in achieving sustained release of ODNs in cell-free systems.
51. Wang S, Lee RJ, Cauchon G, Gorenstein DG, Low PS: Delivery of antisense oligodeoxyribonucleotides against the human epidermal growth factor receptor into cultured KB cells with liposomes conjugated to folate polyethylene glycol. Proc Natl Acad Sci U S A 1995, 92:3318-3322.
52. Lewis JG, Lin KY, Kothavale A, Flanagan WM, Matteucci MD, Deprince RB, Mook RA JR, Hendren RW, Wagner RW: A serum-resistant cytofectin for cellular delivery of antisense oligodeoxynucleotides and plasmid DNA. Proc Natl Acad Sci U S A 1996, 93:3176-3181. This report describes development of a novel lipofectamine that represents a major improvement over existing reagents for ODN delivery. This formulation delivers ODNs and plasmids into many (but not all) cell types. Although the mechanism is not clear, it appears to destabilize the endosomal membranes, permitting entry of ODNs into the cytoplasm. Once in the nucleus, the ODNs are not diffused back into the cytoplasm. This formulation enabled the use of nanomolar concentrations of PS ODNs and may thus circumvent the nonspecificity seen with these ODNs at high concentrations.
53. Zhang R, Yan J, Shahinian H, Amin G, Lu Z, Liu T, Saag MS, Jiang Z, Temsamani J, Martin RR, Schechter PJ, Agrawal S, Diasio RB: Pharmacokinetics of an anti-HIV antisense oligodeoxynucleotide phosphorothioate (GEM 91) in HIV-infected subjects. Clin Pharmacol Ther 1995, 58:44-53.
54. Agrawal S, Temsamani J, Galbraith W, Tang J: Pharmacokinetics of antisense oligonucleotides. Clin Pharmacokinet 1995, 28:7-16. A comprehensive pharmacokinetics study of PO, PS, and MP ODNs in mice, rats, monkeys, and humans.
55. Agrawal S, Zhang X, Lu Z, Zhao H, Tamburin JM, Yan J, Cai H, Diasio RB, Habus I, Jiang Z, Iyer RP, Yu D, Zhang R: Adsorption, tissue distribution and in vivo stability in rats of a hybrid antisense oligonucleotide following oral administration. Biochem Pharmacol 1995, 50:571-576. The ability to administer ODNs orally would greatly simplify their therapeutic use. This is the first report of such delivery. Hybrid ODNs were shown to be absorbed intact through the gastrointestinal tract, a finding that may be important in the development of antisense ODNs as therapeutic agents.
56. Bishop MR, Iversen PL, Bayever E, Sharp JG, Greiner TC, Copple BL, Ruddon R, Zon G, Spinolo J, Arneson M, Armitage JO, Kessinger A: Phase I trial of an antisense oligonucleotide OL(1)p53 in hematologic malignancies. J Clin Oncol 1996, 14:1320-1326.
57. Gao WY, Han FS, Storm C, Egan W, Cheng YC: Phosphorothioate oligonucleotides are inhibitors of human DNA polymerases and RNase H: Implications for antisense technology. Mol Pharmacol 1992, 41:223-229.
58. Maury G, Abdelaziz E, Morvan F, Muller B, Imbach J, Goody RS: Template, phosphorothioate oligonucleotides duplexes as inhibitors of HIV-1 reverse transcriptase. Biochem Biophys Res Commun 1992, 186:1249-1256.
59. Stein CA, Neckers LM, Nair BC, Mumbauer S, Hoke G, Pal R: Phosphorothioate oligodeoxycytidine interferes with binding of HIV-1 and HIV-2 in vitro. J Acquir Immune Defic Syndr 1991, 4:686-693.
60. Sharma HW, Hsiao R, Narayanan R: Telomerase as a potential molecular target to study G-quartet phosphorothioates. Antisense Res Dev 1996, 6:3-7. This is yet another example of the nonspecific effects of G-quartet containing PS ODNs. Depending on the context of their occurrence, G-quartet PS ODNs inhibited telomerase (an enzyme implicated in cell senescence and immortalization) activity in vitro. Phosphodiester and MP ODNs had no effect.
61. Brown DA, Kang SH, Gryaznov SM, Dedionisio L, Heidenreich O, Sullivan S, Xu X, Nerenberg MI: Effect of phosphorothioate modification of oligodeoxynucleotides on specific protein binding. J Biol Chem 1994, 269:26801-26805.
62. Perez JR, Li Y, Stein CA, Majumder S, Van Oorschot A, Narayanan R: Sequence independent induction of Sp-1 transcription factor by phosphorothioate oligodeoxynucleotides. Proc Natl Acad Sci U S A 1994, 91:5957-5961.
63. Branda RF, Moore AL, Mathews L, McCormack JJ, Zon G: Immune stimulation by an antisense oligomer complementary to the rev gene of HIV-I. Biochem Pharmacol 1993, 45:2037-2043.
64. McIntyre KW, Lombard-Gillooly K, Perez JR, Kunsch C, Sarmiento UM, Larigan JD, Landreth KT, Narayanan R: A sense phosphorothioate oligonucleotide directed to the Initiation codon of transcription factor NF-κB p65 causes sequence-specific immune stimulation. Antisense Res Dev 1993, 3:309-322.
65. Krieg AM, Yi AK, Matson S, Waldschmidt TJ, Bishop GA, Teasdale R, Koretzky GA, Klinman DM: CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 1995, 374:546-549.
66. Khaled Z, Benimetskaya L, Zeeitser R, Khan T, Sharma HW, Narayanan R, Stein CA: Multiple mechanisms may contribute to the cellular anti-adhesive effects of phosphorothioate oligodeoxynucleotides. Nucleic Acids Res 1996, 24:737-745.